IL10 and Arthritis: Likewise, Stoop et al. demonstrated that the inhibition of arthritis severity and progression following treatment with type II collagen-pulsed tolDC was not accompanied by an expansion of splenic Foxp3-positive Tregs, but by an increase in the number of IL-10-producing T cells and a decrease in IL-17-producing T cells [8].